Clinical Trial Detail

NCT ID NCT02983006
Title Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors New York University School of Medicine
Indications

melanoma

Therapies

DS-8273a + Nivolumab

Age Groups: senior adult

No variant requirements are available.